Summary
Fidelity Advisor Biotechnology Fund is a mutual fund. It does not trade on an exchange: you buy it from the fund company at a price set once a day. Positions inside: 118. The ten largest make up 46% of the fund.
- Positions
- 118
- Dividend yield
- 1.30%
What speaks for it
- Average yearly growth over the last ten years: 7.8%.
What to watch
- In the last five years its price once dropped by 50% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -5.1%
- 3 months
- -0.2%
- This year
- +21%
- 1 year
- +25%
- 3 years
- +98%
- 5 years
- +33%
- 10 years
- +112%
- Avg. market cap
- $113.5B
- P/E
- -
- Forward P/E
- -
- P/S
- 10.5x
- P/B
- 5.5x
- P/FCF
- -
- EV/EBITDA
- -
- Dividend yield
- 0.60%
- ROIC
- -15.7%
- ROE
- -16.9%
- Gross margin
- -940.0%
- Operating margin
- -6,382.9%
- Net margin
- -5,274.2%
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.62
Weighted average of the 50 largest companies, which make up 89% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Moderately concentrated- 1 ABAbbVie ABBV 14%
- 2 GIGilead Sciences GILD 6.0%
- 3 ALAlnylam Pharmaceuticals ALNY 3.8%
- 4 INInsmed INSM 3.4%
- 5 AMAmylyx Pharmaceuticals, Inc. AMLX 3.4%
- 6 ARArgenx ARGX 3.3%
- 7 DNDianthus Therapeutics, Inc. DNTH 3.2%
- 8 SYSpyre Therapeutics, Inc. SYRE 3.2%
- 9 MRModerna MRNA 3.1%
- 10 RVRevolution Medicines RVMD 3.0%
Positions in the fund: 118. The ten largest make up 46% of it.
Composition as of Oct 18, 2026.
Where is it spread?
By company size
- Mega cap 17%
- Large cap 36%
- Mid cap 35%
- Small cap 11%
- Micro cap 1.4%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest size group: Large cap (36%).
What does it cost me?
We do not know the costs of this fund.
How has it done?
Growing over the long run- A year on average, 10 years
- +7.8%
- Deepest drop
- -50%
- Yearly volatility
- 25%
Average yearly growth over the last ten years: 7.8%. Deepest drop in these years: 50% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 1.30%
- Payments a year
- 1
- Last payment
- $0.52
Over the last 12 months it paid $0.52 per share, which is 1.30% of today's price. The last payment was $0.52 on Dec 26, 2025.
How expensive are the companies inside?
Rather expensive- Average Bulios Score
- 44 out of 100
Weight by Bulios Fair Price
- Undervalued 18%
- Fairly valued 7.8%
- Overvalued 74%
By Fair Price, 74% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 89% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Can I buy it as an ETF?
A mutual fund is bought from the fund company. These ETFs hold much of the same and trade on an exchange, so an ordinary broker carries them.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
TD TDNA T. Rowe Price Biotech ETF | United States | 0.55% | $9.09M | - | - | 39% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $10.5B | +30% | Pays out | 36% |
FM FMED Fidelity Disruptive Medicine ETF | United States | 0.50% | $69.3M | +16% | Pays out | 36% |
CU CURE.AX Global X - S&P Biotech ETF | Australia | 0.45% | $27.4M | +25% | Reinvests | 35% |
XB XBI SPDR S&P Biotech ETF | United States | 0.35% | $7.55B | +34% | Pays out | 35% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $906.2M | +37% | Reinvests | 33% |
